208 related articles for article (PubMed ID: 37516994)
41. Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response.
Strowd RE; Salvatori R; Laterra JJ
J Oncol Pharm Pract; 2016 Jun; 22(3):517-22. PubMed ID: 25616657
[TBL] [Abstract][Full Text] [Related]
42. Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.
Lasolle H; Cortet C; Castinetti F; Cloix L; Caron P; Delemer B; Desailloud R; Jublanc C; Lebrun-Frenay C; Sadoul JL; Taillandier L; Batisse-Lignier M; Bonnet F; Bourcigaux N; Bresson D; Chabre O; Chanson P; Garcia C; Haissaguerre M; Reznik Y; Borot S; Villa C; Vasiljevic A; Gaillard S; Jouanneau E; Assié G; Raverot G
Eur J Endocrinol; 2017 Jun; 176(6):769-777. PubMed ID: 28432119
[TBL] [Abstract][Full Text] [Related]
43. [Intracranial metastasis of pituitary adenoma: a case report].
Taya K; Terao T; Nakazaki H; Sawauchi S; Numoto RT; Murakami S; Yamaguchi Y; Hashimoto T; Abe T
No Shinkei Geka; 2004 Mar; 32(3):279-84. PubMed ID: 15148803
[TBL] [Abstract][Full Text] [Related]
44. The role of temozolomide in the treatment of aggressive pituitary tumors.
Liu JK; Patel J; Eloy JA
J Clin Neurosci; 2015 Jun; 22(6):923-9. PubMed ID: 25772801
[TBL] [Abstract][Full Text] [Related]
45. Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician's questions.
Trouillas J; Jaffrain-Rea ML; Vasiljevic A; Dekkers O; Popovic V; Wierinckx A; McCormack A; Petersenn S; Burman P; Raverot G; Villa C
Rev Endocr Metab Disord; 2020 Jun; 21(2):243-251. PubMed ID: 32504268
[TBL] [Abstract][Full Text] [Related]
46. Pituitary carcinoma: a clinicopathologic study of 15 cases.
Pernicone PJ; Scheithauer BW; Sebo TJ; Kovacs KT; Horvath E; Young WF; Lloyd RV; Davis DH; Guthrie BL; Schoene WC
Cancer; 1997 Feb; 79(4):804-12. PubMed ID: 9024719
[TBL] [Abstract][Full Text] [Related]
47. Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas.
Das L; Gupta N; Dutta P; Walia R; Vaiphei K; Rai A; Radotra BD; Gupta K; Sreedharanunni S; Ahuja CK; Bhansali A; Tripathi M; Sood R; Dhandapani S
Front Endocrinol (Lausanne); 2021; 12():774686. PubMed ID: 34975752
[TBL] [Abstract][Full Text] [Related]
48. [Atypical pituitary tumors].
Krysiak R; Okopień B; Korzekwa M
Pol Merkur Lekarski; 2012 May; 32(191):323-8. PubMed ID: 22779341
[TBL] [Abstract][Full Text] [Related]
49. Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.
Annamalai AK; Dean AF; Kandasamy N; Kovacs K; Burton H; Halsall DJ; Shaw AS; Antoun NM; Cheow HK; Kirollos RW; Pickard JD; Simpson HL; Jefferies SJ; Burnet NG; Gurnell M
Pituitary; 2012 Sep; 15(3):276-87. PubMed ID: 22076588
[TBL] [Abstract][Full Text] [Related]
50. Recurrent pituitary adenomas.
Marguth F; Oeckler R
Neurosurg Rev; 1985; 8(3-4):221-4. PubMed ID: 4033962
[TBL] [Abstract][Full Text] [Related]
51. Current Status of Diagnosis and Management for Functioning Pituitary Tumors: Part I.
Thakkar K; Sarathi V; Shah NS
Neurol India; 2020; 68(Supplement):S13-S19. PubMed ID: 32611887
[TBL] [Abstract][Full Text] [Related]
52. Evolution of a refractory prolactin-secreting pituitary adenoma into a pituitary carcinoma: report of a challenging case and literature review.
Dai C; Sun B; Guan S; Wang W; Liu H; Li Y; Zhang J; Kang J
BMC Endocr Disord; 2021 Oct; 21(1):217. PubMed ID: 34715828
[TBL] [Abstract][Full Text] [Related]
53. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.
Thapar K; Scheithauer BW; Kovacs K; Pernicone PJ; Laws ER
Neurosurgery; 1996 Apr; 38(4):765-70; discussion 770-1. PubMed ID: 8692397
[TBL] [Abstract][Full Text] [Related]
54. [Thyrotropin-secreting pituitary adenoma].
Sohár G; Györkös A; Dóczi T; Kajtár B; Piski Z; Kovács M
Orv Hetil; 2020 Mar; 161(12):474-478. PubMed ID: 32172585
[TBL] [Abstract][Full Text] [Related]
55. Management of Nonfunctioning Recurrent Pituitary Adenomas.
Farrell CJ; Garzon-Muvdi T; Fastenberg JH; Nyquist GG; Rabinowitz MR; Rosen MR; Evans JJ
Neurosurg Clin N Am; 2019 Oct; 30(4):473-482. PubMed ID: 31471054
[TBL] [Abstract][Full Text] [Related]
56. Giant pituitary adenoma: histological types, clinical features and therapeutic approaches.
Iglesias P; Rodríguez Berrocal V; Díez JJ
Endocrine; 2018 Sep; 61(3):407-421. PubMed ID: 29909598
[TBL] [Abstract][Full Text] [Related]
57. Current perspectives on recurrent pituitary adenoma: The role and timing of surgery vs adjuvant treatment.
Hayhurst C; Taylor PN; Lansdown AJ; Palaniappan N; Rees DA; Davies JS
Clin Endocrinol (Oxf); 2020 Feb; 92(2):89-97. PubMed ID: 31715012
[TBL] [Abstract][Full Text] [Related]
58. A Silent Corticotroph Pituitary Carcinoma: Lessons From an Exceptional Case Report.
Remón-Ruiz P; Venegas-Moreno E; Dios-Fuentes E; Moreno JMC; Fernandez Peña I; Garcia MA; Japón-Rodriguez MA; Roldán F; Fajardo E; Kaen A; Ruiz-Valdepeñas EC; Cano D; Soto-Moreno A
Front Endocrinol (Lausanne); 2021; 12():784889. PubMed ID: 34992581
[TBL] [Abstract][Full Text] [Related]
59. Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases.
Losa M; Mazza E; Terreni MR; McCormack A; Gill AJ; Motta M; Cangi MG; Talarico A; Mortini P; Reni M
Eur J Endocrinol; 2010 Dec; 163(6):843-51. PubMed ID: 20870708
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
